Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL747 in Amyotrophic Lateral Sclerosis
NCT03757351Phase 1Terminated
- Sponsor
- Sanofi
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DNL747 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Sanofi. Primary endpoints: Treatment-Emergent Adverse Events at Day 86, Serious Adverse Events at Day 86 and 2 more. Started Dec 2018; status: terminated.
02
Drugs
DNL747
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03757351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757351.